Frequently Asked Questions:
The Americas and Europe Chagas disease drugs market was valued at USD 315.9 Billion in 2022.
The Americas and Europe Chagas disease drugs market are expected to grow at a CAGR of 6.80% between 2023 and 2030, reaching USD 500.666 Billion in 2030.
Benznidazole is the leading segment by drug type, holding over 43% share in terms of value in 2022.
The Antiparasitic treatment segment governs the demand for Americas and Europe Chagas disease drugs worldwide, holding a massive share of over 80% in 2022.
The symptomatic treatment segment is expected to post the highest CAGR during the forecast period.
U.S. is fueling the growth of the Americas and Europe chagas disease drugs industry, with over one-third share in 2022.
The top players include AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co Ltd, Eisai Co Ltd, GlaxoSmithKline Plc, Grupo Praxis Pharmaceutical SA, Humanigen Inc, Kancera AB, Merck & Co Inc, Novartis AG, Oblita Therapeutics BVBA, and Sanofi
The increased migration and travel are the major market drivers.
Drug development is also complicated by the Chagas disease’s complexity, and the limited knowledge are the major market restraints.
The huge growth potential in the U.S., raising awareness, and enhancing access to healthcare services are the major opportunities in the Americas and Europe chagas disease drugs industry.